Work

Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.7508

Authors: Farhad Ravandi, Roland B. Walter, Marion Subklewe, Veit Buecklein, Mojca Jongen-Lavrencic, Peter Paschka, Gert J. Ossenkoppele, Hagop M. Kantarjian, Antreas Hindoyan, Suresh K Agarwal, Tian Dai, Sophia Khaldoyanidi, Anthony Selwyn Stein

Institutions: The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, LMU Klinikum, Ludwig-Maximilians-Universität München, Erasmus MC, Universität Ulm, University Hospital Ulm, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amgen (United States), City Of Hope National Medical Center, City of Hope

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W3029593460

Cites:

Cited by: 104

Related to: 10